TGFB1 and cancer: The ARMG risk score showed significantly positive relation with immunoinhibitors TGFB1 and VTCN1, and was negatively related with immunostimulators CD27, CD28, CD40LG, CD80, ENTPD1 and ICOS in pan-cancer (Figure 8G).